imatinib mesylate has been researched along with Mast Cell Activation Disease in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (55.56) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Gotlib, J | 1 |
| Ali, N; Boigon, M; Fidler, C; Ghani, A; Hamid, M; Jafri, SIM; Malik, F | 1 |
| Bonkobara, M; Kobayashi, M; Nakano, Y; Takanosu, M | 1 |
| Bryon, J; Needham, SJ; Nicolle, A; Panter, S; Speight, RA; Verrill, MW | 1 |
| Fukazawa, E; Kobayashi, T; Nakano, Y; Oshima, F; Shiraishi, Y; Takanosu, M; Yamagami, T | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Alfonso, A; Botana, LM; Tobío, A | 1 |
| Bonkobara, M; Kobayashi, M; Kozutumi, Y; Kuroki, S; Moriya, Y; Ono, K; Tamura, K; Tanaka, Y; Uehara, Y; Washizu, T | 1 |
| Ashman, LK; Braue, A; Byrnes, E; Ferrao, P; Foster, R; Griffith, R; Meldrum, C; Ross, G; Scott, R; Upjohn, E; Varigos, G | 1 |
| Allione, B; Caira, M; Candoni, A; Caramatti, C; Cattaneo, C; Fanci, R; Ferrara, F; Fianchi, L; Giona, F; Iannitto, E; Invernizzi, R; Leone, G; Lunghi, M; Marbello, L; Martinelli, G; Musto, P; Pagano, L; Pogliani, EM; Pulsoni, A; Rondoni, M; Sanpaolo, G; Stefani, PM; Valentini, CG; Van Lint, MT | 1 |
| Cancelas, JA; Rothenberg, ME; Yamada, Y | 1 |
| Bonkobara, M; Fujino, Y; Isotani, M; Lachowicz, JL; Ono, K; Tamura, K; Washizu, T; Yagihara, H; Yamada, O | 1 |
| Gotlib, J; Pardanani, A; Tefferi, A | 1 |
| Hoffman, R; Kiladjian, JJ; Mesa, RA | 1 |
| Colicelli, J; Janson, C; Kasahara, N; Prendergast, GC | 1 |
| Akin, C; Cools, J; Gilliland, DG; Klion, AD; Law, MA; Metcalfe, DD; Noel, P; Nutman, TB | 1 |
| Akin, C; Brockow, K; D'Ambrosio, C; Kirshenbaum, AS; Longley, BJ; Ma, Y; Metcalfe, DD | 1 |
| Pardanani, A; Tefferi, A | 2 |
| O'Brien, S; Tefferi, A; Valent, P | 1 |
| Cavenagh, JD; Cross, NC; Fitzgibbon, J; Lister, TA; Melo, JV; Schultheis, B; Smith, ML; Zhang, LY | 1 |
| Bainbridge, T; Corless, CL; Gatter, K; Granter, S; Harrell, P; Heinrich, MC; Lacouture, M; Le, C; White, C | 1 |
| Akin, C; Hungness, SI | 1 |
| Escribano, L; Garcia-Montero, AC; Orfao, A; Sanchez, L | 1 |
| Sotlar, K | 1 |
| Akin, C; Butterfield, JH; Dimitrijevic, S; Longley, BJ; Ma, Y; McMahon, G; Metcalfe, DD; Zeng, S | 1 |
| Hochhaus, A | 1 |
11 review(s) available for imatinib mesylate and Mast Cell Activation Disease
| Article | Year |
|---|---|
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Topics: Child; Eosinophilia; Humans; Imatinib Mesylate; Mastocytosis; Mastocytosis, Systemic; Myeloproliferative Disorders; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2022 |
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Topics: Animals; Benzamides; Chronic Disease; Disease Models, Animal; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis; Mice; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction | 2009 |
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Causality; Decision Trees; Diagnosis, Differential; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Mastocytosis; mRNA Cleavage and Polyadenylation Factors; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor | 2010 |
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential | 2011 |
Clinical, genetic, and therapeutic insights into systemic mast cell disease.
Topics: Adult; Benzamides; Cladribine; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2004 |
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 5; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mastocytosis; Metaplasia; Mutation; Myeloproliferative Disorders; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic | 2004 |
Chronic myelogenous leukemia and myeloproliferative disease.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Piperazines; Primary Myelofibrosis; Pyrimidines | 2004 |
Mastocytosis: advances in diagnosis and treatment.
Topics: Amino Acid Substitution; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Tyrosine | 2007 |
Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Topics: Benzamides; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Mast Cells; Mastocytosis; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2007 |
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors | 2002 |
1 trial(s) available for imatinib mesylate and Mast Cell Activation Disease
| Article | Year |
|---|---|
Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Cat Diseases; Cats; DNA Mutational Analysis; DNA, Neoplasm; Drug Evaluation, Preclinical; Exons; Imatinib Mesylate; Immunoglobulin D; Mastocytosis; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2010 |
15 other study(ies) available for imatinib mesylate and Mast Cell Activation Disease
| Article | Year |
|---|---|
Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.
Topics: Adolescent; Diphenhydramine; Female; Histamine H1 Antagonists; Humans; Imatinib Mesylate; Infusions, Parenteral; Mastocytosis; Protein Kinase Inhibitors; Quality of Life; Treatment Outcome | 2017 |
Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.
Topics: Animals; Antineoplastic Agents; Dogs; Drug Resistance, Neoplasm; Imatinib Mesylate; Mastocytosis; Proto-Oncogene Proteins c-kit; Sequence Deletion | 2017 |
Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Immunohistochemistry; Intestine, Small; Male; Mastocytosis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2013 |
Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11.
Topics: Animals; Base Sequence; Benzamides; Dog Diseases; Dogs; Female; Gene Components; Imatinib Mesylate; Lymphatic Metastasis; Male; Mastocytosis; Molecular Sequence Data; Mutation, Missense; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Sequence Deletion; Treatment Outcome | 2014 |
PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Synergism; Enzyme Activation; Flow Cytometry; Humans; Imatinib Mesylate; Mastocytosis; Piperazines; Protein Kinase C; Protein Kinase C-delta; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Transfection | 2014 |
Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Mutational Analysis; Dogs; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Imatinib Mesylate; Mastocytosis; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; STAT3 Transcription Factor | 2015 |
Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Topics: Adolescent; Amino Acid Substitution; Benzamides; Cell Proliferation; Child; Child, Preschool; Diseases in Twins; Exons; Female; Humans; Imatinib Mesylate; Infant; Male; Mastocytosis; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Proto-Oncogene Proteins c-kit; Pyrimidines; Twins, Monozygotic | 2008 |
Advanced mast cell disease: an Italian Hematological Multicenter experience.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Antiviral Agents; Benzamides; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Italy; Liver; Male; Mastocytosis; Middle Aged; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Retrospective Studies; Spleen; Survival Rate; Transplantation, Homologous | 2008 |
RIN3 is a negative regulator of mast cell responses to SCF.
Topics: Benzamides; Carrier Proteins; Cell Movement; Cell Proliferation; Endocytosis; Gene Expression Regulation; Gene Silencing; Guanine Nucleotide Exchange Factors; Humans; Imatinib Mesylate; Immunohistochemistry; Inflammation; Lipopolysaccharide Receptors; Mast Cells; Mastocytosis; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; rab5 GTP-Binding Proteins; Stem Cell Factor | 2012 |
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Base Sequence; Benzamides; Biopsy; Bone Marrow; Chromosomes, Human, Pair 4; Endomyocardial Fibrosis; Eosinophils; Female; Fibrosis; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocytes, Mononuclear; Lung Diseases; Male; Mast Cells; Mastocytosis; Middle Aged; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA; Serine Endopeptidases; Splenomegaly; Tryptases; Vitamin B 12 | 2003 |
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Bone Marrow Cells; Cells, Cultured; Codon; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Male; Mast Cells; Mastocytosis; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; U937 Cells | 2003 |
A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Chromatography, High Pressure Liquid; DNA Primers; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Mastocytosis; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Splicing | 2006 |
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
Topics: Adult; Aged; Alleles; Animals; Benzamides; Cell Line; Female; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Mastocytosis; Mice; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity | 2006 |
[Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Topics: Amino Acid Substitution; Benzamides; Codon; Humans; Imatinib Mesylate; Mastocytosis; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
Topics: Animals; Apoptosis; Benzamides; Catalytic Domain; Cell Division; Drug Resistance; Enzyme Inhibitors; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis; Mutation, Missense; Phosphotransferases; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tumor Cells, Cultured | 2002 |